GlassScriptPhysician profile
Maher Fanous
NPI 1912175480
$6,964.60
in general payments reported to CMS, 2019-2025
20 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $1,325 · 2021: $726 · 2022: $849 · 2023: $474 · 2024: $1,068 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,310.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,340.33 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Abbvie INC. | $1,014.90 | 2022-2025 | |
| Allergan, INC. | $871.99 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $774.08 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $625.67 | 2020-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $511.08 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $393.37 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $388.30 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sight Sciences, INC. | $363.11 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Novartis Pharmaceuticals Corporation | $131.44 | 2019-2021 | |
| Ocular Therapeutix, INC. | $114.15 | 2023-2025 | Dextenza |
| Harrow Eye, LLC | $95.62 | 2024-2025 | Vevye |
| Dompe US, INC. | $94.96 | 2025 | Oxervate |
| Biotissue Holdings INC. | $71.56 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $42.96 | 2024 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $39.44 | 2025 | Omidria |
| Amgen INC. | $32.96 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $22.33 | 2019 | |
| New World Medical,INC. | $21.52 | 2019 | |
| Ivantis, INC | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Fanous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.